| Literature DB >> 34257802 |
Yuan Zhou1, Shanshan Zhang1, Xiang Fan1,2.
Abstract
Stroke is the second most common cause of death globally and the leading cause of death in China. The pathogenesis of cerebral ischemia injury is complex, and oxidative stress plays an important role in the fundamental pathologic progression of cerebral damage in ischemic stroke. Previous studies have preliminarily confirmed that oxidative stress should be a potential therapeutic target and antioxidant as a treatment strategy for ischemic stroke. Emerging experimental studies have demonstrated that polyphenols exert the antioxidant potential to play the neuroprotection role after ischemic stroke. This comprehensive review summarizes antioxidant effects of some polyphenols, which have the most inhibition effects on reactive oxygen species generation and oxidative stress after ischemic stroke.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34257802 PMCID: PMC8253632 DOI: 10.1155/2021/5471347
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The chemical structures and plant origin of some common polyphenols and their classifications.
Antioxidant activity of flavonoids in ischemic stroke related studies.
| Flavonoids | Cell/animal model | Dosages and methods of administration in animal models | Antioxidation-related indexes | Ref |
|---|---|---|---|---|
| Baicalein | OGD cell model (SH-SY5Y) | In vitro: 0.1, 0.25, 0.5, 1, 2, 4, and 8 | Up: NQO1, Nrf2, GSH-Px, SOD, GSH, and CAT | [ |
| OGD cell model (SH-SY5Y) | In vitro: 1, 5, 10, 15, and 20 | Up: MMP | [ | |
| Iodoacetic acid-induced oxidative injury cell model (HT22) | In vitro: 1, 2, 5, and 10 | Up: cell survival | [ | |
|
| ||||
| Baicalin | Primary rat astrocytes and cortical neurons | In vitro: 0.1 to 100 | Down: SDH and ROS | [ |
| OGD cell model (SH-SY5Y) | In vitro: 0.1, 1, and 10 | Down: superoxide and peroxynitrite | [ | |
| Transient global ischemia Mongolian gerbil model | 50, 100, and 200 mg/kg; daily for 7 days, intraperitoneal injection | Up: SOD, GSH, and GSH-Px | [ | |
|
| ||||
| EC | H2O2 and tert-butyl hydroperoxide-simulatedmice embryonic cortical neuronal cells | In vitro: 0.1, 1, 10, and 100 | Up: HO-1 and nuclear Nrf2 | [ |
| OGD cell model (primary mice cortical neurons) | In vitro: 50 and 100 | Up: HO-1, FTL, and BVR | [ | |
|
| ||||
| ECG | OGD cell model (HBMECs) | 0.5, 1, 2, and 4 | Up: SOD | [ |
|
| ||||
| EGCG | MCAO rat model (SD) | 20 mg/kg, intraperitoneal injection. | Up: GSH-Px and SOD | [ |
| MCAO mouse model (C57BL/6) | 50 mg/kg, intraperitoneal injection. | Up: Nrf2 and SOD1 | [ | |
| Dimethylarginine-induced HBMECs injury | 20, 40, 60, 80, and 100 | Down: ROS and MDA | [ | |
| MCAO rat model (SD) | 40 mg/kg; daily for 3 days, intraperitoneal injection. | Up: GSH, Nrf2, HO-1, GCLC, and GCLM | [ | |
| MCAO rat model (SD) | 10 mg/kg; one time for 1 h before surgery and daily for Day 4 to Day 7 after surgery, intragastric administration | Up: GSH and SOD | [ | |
| Glutamate-induced oxidative injury cell model (HT-22) | 1, 10, 50, and 100 100 | Up: HO-1 | [ | |
|
| ||||
| Quercetin | OGD cell model (hippocampal slices and neuron/glia cultures) | In vitro: 10 | Up: HO-1 | [ |
| MCAO rat model (SD) | 10 mg/kg 30 mins before surgery, intraperitoneal injection | Oxidative stress-related proteins | [ | |
| MCAO gerbil model | 20 mg/kg 30; daily for 21 days before surgery, intragastric administration. | Up: SOD1, SOD2, CAT, and GSH-Px | [ | |
| MCAO rat model (SD) | 30 mg/kg 30; daily for 14 days, intraperitoneal injection. | Up: GSH, GSH-Px, and GRx | [ | |
| MCAO rat model (SD) | 30 mg/kg 30 mins before surgery, 0, 24, 48, and 72 h after surgery, intraperitoneal injection | Up: GSH, GR, GSH-Px, GST, SOD, and CAT | [ | |
|
| ||||
| Astragaloside IV | OGD cell model (SH-SY5Y) | In vitro: 10, 30, and 60 | Up: SOD | [ |
| OGD cell model (neurons) | 6.25, 12.5, and 25 | Up: mitochondrial potential, ATP | [ | |
| TIA mouse model (C57BL/6L) | 50 mg/kg two times every day for 12 weeks, intragastric administration | Up: T-AOC, SOD, GSH | [ | |
| LPS stimulated bEnd.3 cells and C57BL/6 mice | In vitro: 25, 50 and 100 | Up: Nrf2, HO-1, and NQO1 | [ | |
| OGD cell model (murine cortical neurons) | 1, 10, 25, and 50 | Up: HO-1, NQO1, and SRXN1 | [ | |
| MCAO mouse model (C57/B6) | 20 and 40 mg/kg 0, 24, and 48 h after surgery, intraperitoneal injection | Up: GSH-Px and SOD | [ | |
|
| ||||
| Genistein | MCAO rat model (SD) | 10 mg/kg daily for 7 days before surgery, intraperitoneal injection | Up: Nrf2 and NQO1 | [ |
| MCAO rat model (SD) | 10 mg/kg 5 mins after surgery, intraperitoneal injection | Up: SOD and Nrf1 | [ | |
| H2O2-stimulated primary neurons | 0.01, 0.1, and 1 mM | Down: ROS | [ | |
| MCAO mouse model (C57/BL6J) | 2.5, 5, and 10 mg/kg daily for 14 days before surgery, intragastric administration | Up: SOD and GSH-Px | [ | |
|
| ||||
| Rutin | Retinoic acid-induced IMR32 cell differentiation | 0.1 | Down: ROS | [ |
|
| ||||
| Hesperidin | MCAO mouse model (C57BL/6J) | 100 mg/kg daily for 10 days, intraperitoneal injection | Up: GSH, CAT, SOD, and GSH-Px | [ |
| MCAO rat model (Wistar) | 50 mg/kg daily for 15 days before surgery, intragastric administration. | Up: GSH, CAT, SOD, GR, and GSH-Px | [ | |
|
| ||||
| Neohesperidin | MCAO rat model (SD) | 40 mg/kg daily for 21 days before surgery, intraperitoneal injection. | Up: T-AOC, GSH, SOD, CAT, GSH-Px, GR, POD, Nrf2, and HO-1 | [ |
|
| ||||
| Apigenin | OGD cell model (PC12) | 1, 10, and 20 | Up: Nrf2, SOD, GSH-Px, CAT, MMP | [ |
| CoCl2-induced PC12 | In vitro: 1-200 | Up: MMP | [ | |
|
| ||||
| Isoquercetin | OGD cell model (primary hippocampal neurons) | In vitro: 20, 40, and 80 | Up: SOD | [ |
| OGD cell model (primary hippocampal neurons) | In vitro: 25, 50, and 100 | Up: SOD and Nrf2 | [ | |
| MCAO rat model (SD) | 5, 10, and 20 mg/kg daily for 3 days, intragastric administration | Up: SOD and CAT | [ | |
|
| ||||
| Isorhamnetin | MCAO mouse model (ICR) | 0.5 and 5 mg/kg, 0 and 24 hours after reperfusion, intraperitoneal injection | Up: Nrf2 and HO-1 | [ |
| Methylglyoxal plus OGD cell model (HBMECs) | 10 to 100 | Up: GSH | [ | |
|
| ||||
| Phloretin | MCAO rat model (SD) | 20, 40, and 80 mg/kg daily for 14 days before surgery, intraperitoneal injection | Up: Nrf2, SOD, GSH, and GSH-Px | [ |
|
| ||||
| Biochanin A | MCAO rat model (SD) | 10, 20, and 40 mg/kg daily for 14 days before surgery, intraperitoneal injection | Up: SOD, GSH-Px, Nrf2, and HO-1 | [ |
|
| ||||
| Tangeretin | OGD cell model (HBMECs) | 2.5, 5, 10, and 20 | Up: SOD | [ |
|
| ||||
| Morin | MCAO rat model (Wistar) | 30 mg/kg, intraperitoneal injection | Down: ROS and MDA | [ |
|
| ||||
| Breviscapine | MCAO rat model (SD) | 20, 50, and 100 mg/kg daily for 7 days before surgery, intraperitoneal injection | Up: SOD, GSH, and CAT | [ |
|
| ||||
| Hispidulin | MCAO rat model (Wistar) | 50 mg/kg daily for 7 days, intraperitoneal injection | Up: Nrf2, SOD, GSH-Px, and CAT | [ |
|
| ||||
| Myricetin | MCAO rat model (SD) | 1, 5, and 25 mg/kg daily for 7 days before surgery, intragastric administration | Up: SOD and GSH | [ |
| OGD cell model (SH-SY5Y) | In vitro: 0.1, 0.33, 1, 3.3 and 10 nM | Up: Nrf2, HO-1, SOD, CAT, mitochondrial ATP, and MMP | [ | |
|
| ||||
| Xanthoangelol | MCAO rat model (SD) | 50 and 100 mg/kg daily for 3 days, intraperitoneal injection | Up: Nrf2, CAT, SOD and GSH-Px | [ |
|
| ||||
| Kaempferol | MCAO rat model (SD) | 1.75, 3.49, and 6.99 mM daily for 7 days before surgery, intragastric administration | Up: Nrf2, SOD and GSH | [ |
|
| ||||
| Naringenin | OGD cell model (cortical neurons) | In vitro: 20, 40 and 80 | Up: SOD and Nrf2 | [ |
|
| ||||
| Chrysin | MCAO mouse model (C57/BL6) | 30 mg/kg, intraperitoneal injection | Up: SOD | [ |
| MCAO rat model (Wistar) | 10, 30, and 100 mg/kg daily for 21 days before surgery, intragastric administration | Up: GSH-Px | [ | |
|
| ||||
| Icariin | Angiotensin II- (Ang II-) induced hypertension rat model | 10 mg/kg daily for 28 days, intragastric administration | Down: ROS | [ |
|
| ||||
| Icariside II | OGD cell model (PC12) | 12.5, 25, and 50 | Up: MMP, Nrf2, NQO1, and HO-1 | [ |
|
| ||||
| Nobiletin | MCAO rat model (SD) | 10 and 25 mg/kg daily for 3 days before surgery, intraperitoneal injection | Up: Nrf2, HO-1, GSH, and SOD1 | [ |
|
| ||||
| Xanthohumol | OGD cell model (primary neurons) | 0.5 | Up: CAT, SOD, and Nrf2 | [ |
Figure 2Molecular mechanisms of polyphenols as antioxidant supplementations in ischemic stroke.